These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 26992692)

  • 21. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Graded Depth of Response and Neoplastic Plasma Cell Index as Indicators of Survival Outcomes in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant.
    Das N; Dahiya M; Gupta R; Kumar L; Rani L; Gupta A; Farswan A; Sharma A; Sharma OD
    Am J Clin Pathol; 2023 Jan; 159(1):69-80. PubMed ID: 36317501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
    Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
    Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical implication of minimal residual disease monitoring by 10-color flow cytometry in multiple myeloma].
    Yao WQ; Zhu MQ; Yan LZ; Jin S; Shang JJ; Yao Y; Yan S; Liu Y; Wu DP; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):720-725. PubMed ID: 31648471
    [No Abstract]   [Full Text] [Related]  

  • 25. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
    Tao Y; Jin S; Yang D; Pan M; Ouyang W; Liu Y; Wang Y; Zhang W; Mi J
    BMC Cancer; 2024 Apr; 24(1):406. PubMed ID: 38565996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
    Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
    J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.
    Nahi H; Afram G; Uttervall K; Lockmer S; Tätting L; Gahrton G; Kashif M; Alici E; Stromberg O; Klimkowska M; Lund J
    Cancer Med; 2023 Nov; 12(22):20736-20744. PubMed ID: 37921243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.
    Liu J; Yan W; Fan H; Xu J; Li L; Du C; Mao X; Yan Y; Xu Y; Sui W; Deng S; Yi S; Anderson KC; Qiu L; Zou D; An G
    Cancer Res Commun; 2023 Sep; 3(9):1770-1780. PubMed ID: 37680953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.
    Radocha J; Pour L; Pika T; Maisnar V; Špička I; Gregora E; Krejčí M; Minařík J; Machálková K; Straub J; Pavlíček P; Hájek R; Žák P
    Eur J Haematol; 2016 Feb; 96(2):119-27. PubMed ID: 25816709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of lymphocyte patterns in multiple myeloma patients after autologous transplant.
    Stork M; Bezdekova R; Kralova R; Sandecka V; Adam Z; Krejci M; Boichuk I; Knechtova Z; Brozova L; Sevcikova S; Rihova L; Pour L
    Neoplasma; 2021 May; 68(3):519-527. PubMed ID: 33618517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of Pre-Transplant CONUT and Post-Transplant MRD on Prognosis of Patients with Multiple Myeloma after Auto-HSCT].
    Xiong YY; Zhou Q; Chen L; Yu W; Zhang HB; Chen JB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):146-154. PubMed ID: 38387913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.
    Krejci M; Buchler T; Hajek R; Svobodnik A; Krivanova A; Pour L; Adam Z; Mayer J; Vorlicek J
    Bone Marrow Transplant; 2005 Jan; 35(2):159-64. PubMed ID: 15543200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.
    Itälä M; Huhtinen AR; Juvonen V; Kairisto V; Pelliniemi TT; Penttilä TL; Rauhala A; Tienhaara A; Remes K
    Eur J Haematol; 2008 Aug; 81(2):100-6. PubMed ID: 18410542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.
    Pasquini MC; Wallace PK; Logan B; Kaur M; Tario JD; Howard A; Zhang Y; Brunstein C; Efebera Y; Geller N; Giralt S; Hari P; Horowitz MM; Koreth J; Krishnan A; Landau H; Somlo G; Shah N; Stadtmauer E; Vogl DT; Vesole DH; McCarthy PL; Hahn T
    J Clin Oncol; 2024 Aug; 42(23):2757-2768. PubMed ID: 38701390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
    Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
    Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.
    Tovar N; Fernández de Larrea C; Elena M; Cibeira MT; Aróstegui JI; Rosiñol L; Filella X; Yagüe J; Bladé J
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1076-9. PubMed ID: 22430087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship of tumor load parameters before and after autologous stem cell transplantation with clinical prognosis in transplant-eligible patients with multiple myeloma: A retrospective analysis.
    Minakata D; Fujiwara SI; Murahashi R; Nakashima H; Matsuoka S; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Nagayama T; Mashima K; Umino K; Nakano H; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Sato K; Ohmine K; Kanda Y
    Leuk Res; 2022 Jan; 112():106750. PubMed ID: 34798568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
    Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.